Drug Profile
Research programme: adenosine antagonists - elbion NV
Latest Information Update: 20 Jul 2010
Price :
$50
*
At a glance
- Originator elbion NV
- Class
- Mechanism of Action Purinergic P1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 20 Jul 2010 Discontinued - Preclinical for Parkinson's disease in Germany (unspecified route)
- 14 Nov 2008 Biotie Therapies acquires elbion NV
- 05 Dec 2006 4AZA Bioscience has merged with elbion to form elbion NV